Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers.
作者信息
Yu Yingyan
机构信息
Department of General Surgery, Ruijin Hospital, Shanghai Institute of Digestive Surgery, Shanghai Key Laboratory for Gastric Neoplasms, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
出版信息
Cancer Biol Med. 2021 Oct 22;18(4):944-8. doi: 10.20892/j.issn.2095-3941.2021.0491.
Abstract
摘要
相似文献
1
Repurposing glucocorticoids as adjuvant reagents for immune checkpoint inhibitors in solid cancers.将糖皮质激素重新用作实体癌中免疫检查点抑制剂的辅助试剂。
Cancer Biol Med. 2021 Oct 22;18(4):944-8. doi: 10.20892/j.issn.2095-3941.2021.0491.
2
Systemic treatments for metastatic cutaneous melanoma.转移性皮肤黑色素瘤的全身治疗
Cochrane Database Syst Rev. 2018 Feb 6;2(2):CD011123. doi: 10.1002/14651858.CD011123.pub2.
3
Treatment-related adverse events, immune-related adverse events and discontinuation in patients with solid tumors adding adjuvant immune checkpoint blockade: a meta-analysis of 38 randomized controlled trials.实体瘤患者辅助性免疫检查点阻断治疗相关不良事件、免疫相关不良事件及停药情况：38项随机对照试验的荟萃分析
Int J Surg. 2025 Jul 1;111(7):4756-4771. doi: 10.1097/JS9.0000000000002480. Epub 2025 May 20.
4
Immune Checkpoint Inhibitors and Cardiovascular Adverse Events.免疫检查点抑制剂与心血管不良事件
ESC Heart Fail. 2025 Apr 10. doi: 10.1002/ehf2.15281.
5
Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.辅助免疫疗法在肾细胞癌和膀胱癌患者中的应用：系统评价和网络荟萃分析。
Int J Urol. 2024 Jan;31(1):25-31. doi: 10.1111/iju.15319. Epub 2023 Oct 15.
6
Adjuvant Immune Checkpoint Inhibitors for Muscle-Invasive Urothelial Carcinoma: An Updated Systematic Review, Meta-analysis, and Network Meta-analysis.辅助性免疫检查点抑制剂治疗肌层浸润性尿路上皮癌：一项更新的系统评价、荟萃分析和网状荟萃分析
Target Oncol. 2025 Jan;20(1):57-69. doi: 10.1007/s11523-024-01114-4. Epub 2024 Nov 13.
7
The Neonatal Innate Immune Response to Sepsis: Checkpoint Proteins as Novel Mediators of This Response and as Possible Therapeutic/Diagnostic Levers.新生儿对败血症的固有免疫反应：检查点蛋白作为这种反应的新型介质以及可能的治疗/诊断手段。
Front Immunol. 2022 Jul 4;13:940930. doi: 10.3389/fimmu.2022.940930. eCollection 2022.
8
Current studies of immunotherapy in head and neck cancer.头颈部癌免疫治疗的当前研究。
Clin Otolaryngol. 2018 Feb;43(1):13-21. doi: 10.1111/coa.12895. Epub 2017 May 29.
9
The therapeutic potential for JAK inhibitors for immune-related adverse events from checkpoint inhibitors- a review of the literature.JAK抑制剂治疗检查点抑制剂所致免疫相关不良事件的潜在疗效——文献综述
Rheumatology (Oxford). 2025 Jun 30. doi: 10.1093/rheumatology/keaf356.
10
A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC).免疫检查点抑制剂（ICI）作为辅助治疗局限性高危肌肉浸润性尿路上皮癌（MIUC）的系统评价和荟萃分析。
Clin Genitourin Cancer. 2022 Oct;20(5):391-398. doi: 10.1016/j.clgc.2022.04.008. Epub 2022 Apr 25.
引用本文的文献
1
Reprogramming tumor immune microenvironment by milbemycin oxime results in pancreatic tumor growth suppression and enhanced anti-PD-1 efficacy.肟米先菌素重编程肿瘤免疫微环境导致胰腺肿瘤生长抑制和增强抗 PD-1 疗效。
Mol Ther. 2024 Sep 4;32(9):3145-3162. doi: 10.1016/j.ymthe.2024.07.029. Epub 2024 Aug 3.
2
Analyzing the Systems Biology Effects of COVID-19 mRNA Vaccines to Assess Their Safety and Putative Side Effects.分析新冠mRNA疫苗的系统生物学效应以评估其安全性和潜在副作用。
Pathogens. 2022 Jun 29;11(7):743. doi: 10.3390/pathogens11070743.
本文引用的文献
1
Identification of Hub Genes and Small Molecule Drugs Associated with Acquired Resistance to Gefitinib in Non-Small Cell Lung Cancer.非小细胞肺癌中与吉非替尼获得性耐药相关的枢纽基因和小分子药物的鉴定
J Cancer. 2021 Jul 2;12(17):5286-5295. doi: 10.7150/jca.56506. eCollection 2021.
2
Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events.免疫检查点抑制剂相关不良事件的特征及预测因素分析
Cancer Biol Med. 2021 Jul 14;18(4):1118-33. doi: 10.20892/j.issn.2095-3941.2021.0052.
3
Identification of SARS-CoV-2-induced pathways reveals drug repurposing strategies.鉴定 SARS-CoV-2 诱导的通路揭示了药物再利用策略。
Sci Adv. 2021 Jun 30;7(27). doi: 10.1126/sciadv.abh3032. Print 2021 Jun.
4
Dexamethasone suppresses immune evasion by inducing GR/STAT3 mediated downregulation of PD-L1 and IDO1 pathways.地塞米松通过诱导 GR/STAT3 介导的 PD-L1 和 IDO1 途径下调来抑制免疫逃逸。
Oncogene. 2021 Aug;40(31):5002-5012. doi: 10.1038/s41388-021-01897-0. Epub 2021 Jun 26.
5
Glucocorticoids are double-edged sword in the treatment of COVID-19 and cancers.糖皮质激素在治疗新冠病毒肺炎和癌症方面是把双刃剑。
Int J Biol Sci. 2021 Apr 10;17(6):1530-1537. doi: 10.7150/ijbs.58695. eCollection 2021.
6
Reshaping the tumor microenvironment for increasing the distribution of glucose oxidase in tumor and inhibiting metastasis.重塑肿瘤微环境以增加葡萄糖氧化酶在肿瘤中的分布并抑制转移。
J Mater Chem B. 2021 Feb 7;9(5):1424-1431. doi: 10.1039/d0tb02468f. Epub 2021 Jan 19.
7
Multi-omics analysis reveals the genetics and immune landscape of dexamethasone responsive genes in cancer microenvironment.多组学分析揭示了癌症微环境中地塞米松反应性基因的遗传学和免疫格局。
Ann Transl Med. 2020 Nov;8(21):1416. doi: 10.21037/atm-20-3650.
8
Association of steroid use with survival in solid tumours.类固醇使用与实体瘤患者生存的关联。
Eur J Cancer. 2020 Dec;141:105-114. doi: 10.1016/j.ejca.2020.09.020. Epub 2020 Oct 30.
9
Effects of synthetic glucocorticoids on breast cancer progression.合成糖皮质激素对乳腺癌进展的影响。
Steroids. 2020 Dec;164:108738. doi: 10.1016/j.steroids.2020.108738. Epub 2020 Oct 13.
10
Glucocorticoids improve severe or critical COVID-19 by activating ACE2 and reducing IL-6 levels.糖皮质激素通过激活 ACE2 和降低 IL-6 水平来改善重症或危重症 COVID-19。
Int J Biol Sci. 2020 Jun 27;16(13):2382-2391. doi: 10.7150/ijbs.47652. eCollection 2020.
Zotero 插件